• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.

作者信息

Ibba Luciano, Gargiulo Luigi, Vignoli Carlo Alberto, Fiorillo Giovanni, Valenti Mario, Costanzo Antonio, Narcisi Alessandra

机构信息

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

出版信息

J Dermatolog Treat. 2023 Dec;34(1):2241585. doi: 10.1080/09546634.2023.2241585.

DOI:10.1080/09546634.2023.2241585
PMID:37501617
Abstract
摘要

相似文献

1
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study.抗白细胞介素-23药物在中度至重度斑块状银屑病合并既往结核感染患者中的安全性：一项单中心回顾性研究。
J Dermatolog Treat. 2023 Dec;34(1):2241585. doi: 10.1080/09546634.2023.2241585.
2
A drug safety evaluation of risankizumab for psoriasis.利纳西普治疗银屑病的药物安全性评价。
Expert Opin Drug Saf. 2020 Apr;19(4):395-402. doi: 10.1080/14740338.2020.1736034. Epub 2020 Mar 5.
3
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.乌司奴单抗治疗中重度斑块状银屑病且潜伏性结核感染患者的安全性。
Br J Dermatol. 2012 Nov;167(5):1145-52. doi: 10.1111/j.1365-2133.2012.11142.x.
4
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.中度至重度斑块状银屑病合并潜伏性结核患者同时接受古塞库单抗和抗结核治疗的安全性：3期VOYAGE 1和VOYAGE 2试验汇总结果
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1744-1749. doi: 10.1111/jdv.16460. Epub 2020 May 15.
5
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.一项多中心、随机、双盲、安慰剂对照、剂量范围研究，评估 vunakizumab 在中重度斑块型银屑病患者中的疗效和安全性。
J Am Acad Dermatol. 2022 Jul;87(1):95-102. doi: 10.1016/j.jaad.2022.01.005. Epub 2022 Jan 10.
6
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.在潜伏性结核感染的现实环境中，接受司库奇尤单抗治疗的银屑病患者未出现结核病再激活情况。
J Dermatolog Treat. 2022 Aug;33(5):2629-2633. doi: 10.1080/09546634.2022.2062280. Epub 2022 Apr 11.
7
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.司库奇尤单抗治疗合并乙型或丙型肝炎感染的银屑病患者的安全性：一项对49例患者的多中心回顾性队列研究。
J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1203-e1207. doi: 10.1111/jdv.19186. Epub 2023 May 18.
8
Guselkumab for the treatment of moderate-to-severe plaque psoriasis.古塞库单抗用于治疗中度至重度斑块状银屑病。
Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6.
9
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.利纳西珠单抗治疗中重度斑块状银屑病的真实世界疗效和安全性：一项 40 周的多中心回顾性研究。
Acta Derm Venereol. 2021 Nov 30;101(11):adv00605. doi: 10.2340/actadv.v101.283.
10
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.利纳西珠单抗治疗难治性部位斑块状银屑病的疗效：来自两个转诊中心的真实世界经验。
J Dermatolog Treat. 2023 Dec;34(1):2220849. doi: 10.1080/09546634.2023.2220849.

引用本文的文献

1
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis).古塞库单抗在银屑病中的留存率、有效性及安全性：一项260周的真实世界多中心回顾性研究，探讨合并银屑病关节炎-白介素的银屑病（意大利银屑病情况）的作用
Dermatol Ther (Heidelb). 2025 Jul 3. doi: 10.1007/s13555-025-01476-1.
2
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis).优化银屑病中替拉珠单抗的给药剂量：一项为期52周的多中心回顾性研究，比较100 mg和200 mg - IL PSO（意大利银屑病情况）
Dermatol Ther (Heidelb). 2025 Jun;15(6):1427-1440. doi: 10.1007/s13555-025-01416-z. Epub 2025 Apr 23.
3
Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.未进行化学预防的潜伏性结核感染银屑病患者使用白细胞介素抑制剂的安全性：一项系统评价
Acta Derm Venereol. 2025 Mar 3;105:adv42081. doi: 10.2340/actadv.v105.42081.
4
Infections in psoriatic arthritis: association with treatment.银屑病关节炎中的感染：与治疗的关联。
Ther Adv Musculoskelet Dis. 2024 Oct 16;16:1759720X241289201. doi: 10.1177/1759720X241289201. eCollection 2024.
5
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis).一项针对银屑病-IL PSO（意大利银屑病概况）部分缓解者从优特克单抗转换为古塞库单抗的3年多中心研究。
Dermatol Ther (Heidelb). 2024 Nov;14(11):2987-2997. doi: 10.1007/s13555-024-01270-5. Epub 2024 Oct 13.
6
Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study.中国斑块状银屑病患者潜伏性结核或非活动性乙型肝炎病毒感染的再激活风险及乌司奴单抗的有效性：一项28周的回顾性观察研究。
Clin Cosmet Investig Dermatol. 2024 Jun 14;17:1413-1422. doi: 10.2147/CCID.S454971. eCollection 2024.
7
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).司库奇尤单抗在真实世界环境中的有效性、耐受性和药物留存率：一项为期三年的回顾性多中心研究-IL PSO（意大利银屑病概况）
J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495.